Reliance Trust Co. of Delaware decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,461 shares of the biopharmaceutical company’s stock after selling 226 shares during the period. Reliance Trust Co. of Delaware’s holdings in Regeneron Pharmaceuticals were worth $717,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in REGN. Grandfield & Dodd LLC boosted its position in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares during the last quarter. National Pension Service boosted its position in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $323,000. Princeton Capital Management Inc. boosted its position in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares during the last quarter. Finally, CIBC World Markets Inc. boosted its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares during the last quarter. 66.79% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 491.62 on Tuesday. The company has a market cap of $51.90 billion, a P/E ratio of 59.51 and a beta of 1.67. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The company has a 50 day moving average of $499.72 and a 200-day moving average of $420.88.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.42. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The company’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.57 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post $12.80 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Reliance Trust Co. of Delaware” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2017/08/01/regeneron-pharmaceuticals-inc-nasdaqregn-shares-sold-by-reliance-trust-co-of-delaware.html.
REGN has been the topic of several research analyst reports. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price target on the stock. in a report on Monday, May 15th. Jefferies Group LLC reissued a “hold” rating and set a $357.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 12th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 4th. Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target on the stock. in a report on Friday, July 14th. Finally, Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $468.84.
In related news, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the completion of the sale, the executive vice president now owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael S. Aberman sold 2,269 shares of the company’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total transaction of $1,208,060.98. Following the sale, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold 59,396 shares of company stock valued at $28,484,734 in the last three months. Corporate insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
